Related Experiment Video
Updated: Aug 8, 2026
An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
In vitro modulation of activation antigens on human lymphocytes by beta-estradiol
1Research Institute for Human Reproduction, Rabin Medical Center, Petach Tiqva, Israel.
Insights
Beta-estradiol may inhibit specific activation markers on human lymphocytes in vitro. This study observed decreased CD69 expression in most cases, suggesting a potential immunomodulatory role for beta-estradiol.
Area of Science:
- Immunology
- Endocrinology
Background:
- Estrogens, like beta-estradiol, are known to influence immune responses.
- Understanding the in vitro immunomodulatory effects of beta-estradiol on human lymphocytes is crucial for comprehending immune system regulation.
Purpose of the Study:
- To investigate the in vitro immunomodulating effect of beta-estradiol on phytohemagglutinin-stimulated human lymphocyte cultures.
- To examine the expression of activation markers CD25, CD69, and CD71 in response to beta-estradiol.
Main Methods:
- Human lymphocyte cultures from 12 healthy adults (25-35 years) were established.
- Cultures were treated with beta-estradiol or a control for 12 hours.
- Flow cytometry was used to analyze the expression of activation markers CD25, CD69, and CD71.
Main Results:
- Beta-estradiol significantly decreased the expression of CD69 in 10 out of 12 cases.
- A slight, though not statistically significant, decrease in Interleukin-2 receptor expression was also observed.
- No significant differences in CD25 or CD71 expression were noted.
Conclusions:
- In vitro beta-estradiol can inhibit specific activation markers, such as CD69, on phytohemagglutinin-stimulated lymphocytes.
- The study's small sample size precluded defining the role of sex differences.
- Further research with larger cohorts and varying estrogen treatments is recommended.
Problem:
The possible in vitro immunomodulating effect of beta-estradiol on phytohemagglutinin-stimulated human lymphocyte cultures was studied.
Method Of Study:
Lymphocyte cultures from 12 healthy men and women aged 25-35 years were set up for 12 hr in the presence and in the absence of beta-estradiol, and the expression of the activation markers CD25, CD69, and CD71 was examined by flow cytometric analysis with specific fluorescent conjugated antibodies.
Results:
Although the number of cases is small, in 10 of 12 cases in the presence of beta-estradiol in two different concentrations, a significantly decreased expression of CD69 could be observed. A slight decrease could also be observed for the Interleukin-2 receptor expression; however, the difference, in the presence or absence of beta-estradiol, was not significant.
Conclusions:
The results suggest that in vitro addition of beta-estradiol can inhibit, to a certain degree, specific activation markers on phytohemagglutinin-stimulated lymphocytes from young men and women. The present study could not define the role of sex differences because of the small number of samples. A comparison between men and women at various ages in a greater number of cases, as well as studies on activation markers after treatments with estrogens, would be useful.
